<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04075916</url>
  </required_header>
  <id_info>
    <org_study_id>10067385</org_study_id>
    <nct_id>NCT04075916</nct_id>
  </id_info>
  <brief_title>A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients</brief_title>
  <acronym>THINKER-NEXT</acronym>
  <official_title>A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Transplanting Hepatitis C Kidneys into Negative KidnEy Recipients [THINKER-NEXT] study
      will include adult kidney transplant candidates without hepatitis C virus (HCV) infection on
      the transplant waiting list who will consent to kidney transplantation from a deceased donor
      infected with HCV, followed by treatment with a direct acting antiviral. The one-year
      allograft function and one-year risk of CMV infection will be compared between THINKER-NEXT
      kidney transplant recipients and matched recipients who received hepatitis C uninfected
      kidney transplants (these patients are called Transplant Cohort). The mortality rate of
      kidney transplant candidates who enroll in THINKER-NEXT and consent to offers of kidneys from
      HCV-infected donors will be compared to matched wait-listed patients who do not consent to
      receive HCV-infected kidneys (these patients are called Wait-list Cohort). Lastly, renal
      pathologic findings will be compared among HCV-viremic donors and HCV-negative comparator
      donors.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2020</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-treatment sustained virologic response (SVR) to direct-acting antiviral (DAA)</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>The primary analysis will be based on a calculation of SVR rates (number of subjects with SVR-12; negative HCV RNA 12 weeks after completing Epclusa therapy)/(number of subjects treated with Epclusa post-kidney transplantation)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Epclusa (sofosbuvir/velpatasvir)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Epclusa is taken by mouth for 12 weeks as per the FDA label.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epclusa</intervention_name>
    <description>All patients will receive 12 weeks of sofosbuvir/velpatasvir as per the FDA label.</description>
    <arm_group_label>Epclusa (sofosbuvir/velpatasvir)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to provide informed consent

          -  Active waiting list status for isolated kidney transplant

          -  18 to 70 years of age

          -  No living kidney donor

          -  Panel reactive antibody ≤97%

          -  Agreement for participation from patient's transplant nephrologist

        Exclusion Criteria:

          -  Hepatocellular carcinoma

          -  Hepatitis B surface antigen and/or DNA positive

          -  HCV nucleic acid test (NAT) positive (an isolated positive HCV Ab is not an exclusion)

          -  HIV RNA-positive or HIV antibody positive

          -  Other chronic liver disease (excluding non-alcoholic fatty liver disease [NAFLD] with
             normal liver enzymes)

          -  Persistently elevated liver transaminases (defined as the upper limit of normal at the
             reference laboratory)

          -  Significant hepatic fibrosis on screening elastography (Fibroscan value ≥8kPa; equates
             to &gt;F2 fibrosis on the Metavir staging system

          -  Primary Focal Segmental Glomerulosclerosis (FSGS), FSGS recurring in initial
             transplant, or other disease process at high risk of early graft failure per the
             treating transplant nephrologist

          -  Current use of amiodarone (due to interaction with sofosbuvir)

          -  Transplant candidate requires antibody desensitization protocol for transplantation

          -  Female who is pregnant, planning to become pregnant during the study, or
             breast-feeding

          -  Participation in another interventional study of any investigational agent or approved
             medication, or participation in another kind interventional study that the responsible
             investigator deems to be an exclusion from period 6 months prior to screening to last
             study visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Peter Reese, MD, MSCE</last_name>
    <phone>(307) 22-THINK</phone>
    <email>thinker@med.upenn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stacey Prenner, MD</last_name>
    <phone>(307) 22-THINK</phone>
    <email>thinker@med.upenn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jackson Memorial Hospital/University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>David Goldberg, MD, MSCE</last_name>
      <email>dsgoldberg@med.miami.edu</email>
    </contact>
    <contact_backup>
      <last_name>Javier Pagan, MD</last_name>
      <email>jap88@miami.edu</email>
    </contact_backup>
    <investigator>
      <last_name>David Goldberg, MD, MSCE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Christine Durand, MD</last_name>
      <email>ChristineDurand@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Dorry Segev, MD, PhD</last_name>
      <email>dorry@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Christine Durand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Raymond Chung, MD</last_name>
      <email>rtchung@partners.org</email>
    </contact>
    <contact_backup>
      <last_name>Meghan Sise, MD</last_name>
      <email>msise@partners.org</email>
    </contact_backup>
    <investigator>
      <last_name>Raymond Chung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>William Chapman, MD, FACS</last_name>
      <email>chapmanw@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>William Chapman, MD, FACS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital/Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Elizabeth Verna, MD</last_name>
      <email>ev77@cumc.columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sumit Mohan, MD</last_name>
      <email>sm2206@cumc.columbia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Elizabeth Verna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Steve Woodle, MD</last_name>
      <email>steve.woodle@uc.edu</email>
    </contact>
    <investigator>
      <last_name>Steve Woodle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37235</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>David Shaffer, MD, FACS</last_name>
      <email>david.shaffer@vumc.org</email>
    </contact>
    <contact_backup>
      <last_name>Rachel Forbes, MD, MBA</last_name>
      <email>rachel.forbes@vumc.org</email>
    </contact_backup>
    <investigator>
      <last_name>David Shaffer, MD, FACS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 29, 2019</study_first_submitted>
  <study_first_submitted_qc>August 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 3, 2019</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir-velpatasvir drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

